Immediate Impact
1 by Nobel laureates 5 from Science/Nature 56 standout
Citing Papers
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Multiple myeloma
2024 Standout
Works of Michel Delforge being referenced
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
2023
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Michel Delforge | 680 | 483 | 457 | 105 | 981 | |
| Douglas W. Sborov | 564 | 585 | 536 | 113 | 1.1k | |
| Sharmilan Thanendrarajan | 619 | 501 | 449 | 108 | 970 | |
| Aurore Perrot | 805 | 530 | 609 | 128 | 1.1k | |
| Caitlin Costello | 439 | 499 | 451 | 61 | 870 | |
| Rachel Kobos | 431 | 351 | 308 | 65 | 791 | |
| Amit Agarwal | 365 | 348 | 364 | 84 | 955 | |
| Tanya M. Spektor | 392 | 376 | 501 | 66 | 1.0k | |
| Karthik Ramasamy | 881 | 591 | 754 | 134 | 1.2k | |
| Adriana Pleșa | 470 | 299 | 442 | 76 | 1.0k | |
| Zeba N. Singh | 484 | 474 | 351 | 54 | 962 |
All Works
Loading papers...